XARELTO®: Clinical trial for extended treatment and reduction in the risk of recurrence in deep vein thrombosis (DVT) and pulmonary embolism (PE)
The EINSTEIN CHOICE trial studied extended treatment in patients with DVT/PE1
|Mean ± SD||58.8±14.7||58.8±14.7|
|Body mass index|
|Both DVT and PE||15.9%||16.0%|
|Index event asymptomatic or unconfirmed||0.2%||0.6%|
*The decision regarding initiation setting should be based on the prescriber's clinical judgment.
DOAC = direct oral anticoagulant; DVT = deep vein thrombosis; PE = pulmonary embolism; VKA = vitamin K antagonist; VTE = venous thromboembolism.